FAQ

LU 103793

Known as: LU-103793, LU103793 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2007
012319952007

Related topics

Related topics

1 relation

Broader (1)

cemadotin

Related mentions per year

Related mentions per year

1995-2014
1990200020102020
LU 103793
cemadotin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison.
The marine ecosystem that has contributed to the discovery of cytarabine and its fluorinated derivative gemcitabine is now… (More)
Is this relevant?
2003
2003
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer.
LU 103793 is a synthetic analogue of Dolastatin 15 that inhibits tubulin polymerisation. The aim of this study was to evaluate… (More)
Is this relevant?
2003
2003
A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer.
A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with… (More)
Is this relevant?
2001
2001
Activity of the dolastatin analogue, LU103793, in malignant melanoma.
LU103793, a synthetic analogue of dolastatin 15, showed interesting pre-clinical activity in melanoma xenografts. In this phase… (More)
Is this relevant?
1999
1999
Synthesis and cytostatic properties of structure-simplified analogs of dolastatin 15.
The linear peptide dolastatin 15 (1), a potent antineoplastic constituent from the shell-less mollusk Dolabella auricularia, has… (More)
Is this relevant?
1998
1998
Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action.
Cemadotin (LU103793) (NSC D-669356) is a water-soluble synthetic analogue of dolastatin 15 that inhibits cell proliferation in… (More)
Is this relevant?
1998
1998
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic profile of the… (More)
Is this relevant?
1998
1998
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft…
PURPOSE To determine the maximum tolerable dose (MTD), principal toxicity, and pharmacologic behaviour of Cemadotin-HCl, a novel… (More)
Is this relevant?
1995
1995
LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis.
LU103793 (NSC D-669356) is a new synthetic derivative of Dolastatin 15, an antiproliferative compound which was isolated from the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?